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Figure 1

Background

Results

• SARS-CoV-2 (SARS-2) is a newly emerged pandemic
coronavirus which causes COVID-19.

• Co-transduction of A293T cells with a 1:1 or 1:2 ratio of SARS-2 S-protein
expression vector to lentivirus backbone vector at 2.5ug total plasmid DNA
yielded 34.8% and 34.3% transduction efficiencies, respectively. Following
the same protocol, co-transduction with VSV-G envelope construct instead
of SARS-2 S-protein expression vector resulted in 36.9% and 34.2%
transduction efficiencies at 1:1 and 1:2 ratios, respectively (Figure 1, step
2). There is no significant statistical difference between the transduction
efficiencies between the SARS-2 and VSV-G pseudotyping protocol.

• The extent to which those that recover from infection
or are vaccinated are protected from subsequent
infection by their adaptive immunity is not well
understood. This protection comes from neutralizing
antibodies which bind to spike proteins (S-protein) on
the outside of virions, preventing its interaction with
ACE-2 proteins on target cells. The virus is neutralized
because the antibody prevents the virus from infecting
the host cell, and this function can be measured in
convalescent patient serum.

• In huACE-2 non-expressing HEK-293 cells incubated with the generated
pseudotyped particles, GFP expression was observed in those infected
with the VSV-G pseudotyped particles but not with the SARS-2
pseudotyped particles (Figure 1, step 4a).

• To date, it is not known how long these neutralizing
antibodies remain in circulation at high enough titers to
protect against infection months or years after infection
or vaccination. Current COVID-19 serology tests are
only able to determine if the individual tested has
antibodies against the virus or not, but they do not
reveal whether any of the antibodies are neutralizing
antibodies (6).

• A total of 6 GFP-expressing cells identified between 3 of 9 HEK-293-ACE2
cultures infected with a 100-fold dilution of SARS-2 pseudotyped virus
aliquots (Figure 1, step 5)(Figure 3). At the same dilution of VSV-G
pseudotyped virus aliquots, thousands of GFP expressing cells identified
within 2 of 2 cultures.
• Western blot analysis of HEK 293-ACE2 cells confirms the presence of
huACE2 receptor (Figure 2). This assay rules out the possibility that the
absence of GFP expression in the HEK 293-ACE2 cells infected with the
SARS-2 spike-pseudotyped virions was due to the absence of huACE2
receptors.

• Pseudotyped viruses are often generated for use when
using the wildtype infectious virus is considered too
risky and when only one round of infection is required.
• A pseudotyped virus involves generating chimeric virus
particles in which the envelope protein of a virus (i.e.,
SARS-2 spike) is utilized on another viral backbone
that is virtually harmless, because it is missing the
gene for its own envelope protein. It is for this reason
that pseudotyping has been utilized with viruses such
as HIV (3), SARS-CoV-1 (5), and Ebola virus (1).

Discussion / Conclusion
• Further research needs to be performed to identify solutions to
successfully infect huACE2 positive cells with SARS-2 pseudotyped
particles.

Purpose
The objective of this study is to generate SARS-2
pseudotyped retrovirus particles expressing green
fluorescent protein (GFP) when they infect target cells.
The pseudotyped particles will enable us to measure antiS-protein neutralizing antibodies in human serum without
the risks inherent in using infectious SARS-2 for these
assays.

Methods
Generation of envelope and backbone constructs:
• SARS-2 envelope expression construct, VSV-G
envelope construct, and envelope gene-deleted
lentivirus backbone constructs generated from plasmid
DNA expression vectors, amplified in transformed
DH5α E. coli, isolated and purified on columns.

Figure 1. Diagram depicts methods for production and characterization of SARS-2 pseudovirus particles.
1) Co-transfection of A293T cells with a GFP-expressing, envelope gene-deleted lentivirus backbone vector and with an
epitope-tagged SARS-2 S-protein expressing vector (2)(4).
2) GFP expression of transfected A293T cells measured by fluorescence microscopy.
3) Pseudotyped particles harvested from co-transfection culture supernatant (48 hours), concentrated through 100kD
centrifugal filter tubes and stored in small volume aliquots at -80C.
4) Infection of HEK-293 cell lines with pseudotyped particles.
a) No SARS-2 pseudovirus infection in HEK-293 cell line.
b) SARS-2 pseudovirus infection expected in ACE2 expressing HEK-293 cell line.
5) GFP expression of infected HEK-293-ACE2 cells measured by fluorescence microscopy.

Figure 2

Figure 3

Production and characterization of control
pseudovirus:

• Refer to Figure 2.

• This research project was funded by the Touro University Nevada 2020 Mentored
Student Research Award to Luis Sanchez and Karen M. Duus, Ph.D.
• GFP-expressing lentivirus backbone obtained from Dr. Carlos de Noronha laboratory,
Albany Medical College, Albany, NY (2).
• ACE2-expressing HEK-293 cells and SARS-2 envelope expression construct obtained
from the BEI reagent program at the National Institute of Health (NIH).
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